|
1970 |
DRG International, Inc. Is founded by Dr. C.E. Geacintov in New Jersey, USA |
|
1970 |
DRG® enters market in Europe, USSR, Poland and Yugoslavia |
|
1973 |
Distribution of RIA`s in Germanybegins |
|
1973 |
DRG Instruments GmbHis founded in Munich, Germany |
|
1974 |
DRG Instruments GmbH moves to Marburg, Germany |
|
1981 |
DRG® enters the Middle East Markets in Saudi Arabia, Kuwait, and Iran |
|
1981 |
DRG® introduces the Mechanical Heart Valve on European Cardiac Surgery Market |
|
1982 |
DRG® expands in Eastern and Western Europe |
|
1985 |
DRG® begins in-house R&D Operations |
|
1988 |
DRG AG founded in Zürich,Switzerland |
|
1990 |
DRG MEDTEK founded in Warsaw, Poland |
|
1990 |
DRG® begins R&D and ELISA production in Marburg, Germany |
|
1991 |
DRG Biomed founded in St. Petersburg, Russia |
|
1991 |
DRG® launches first neonatal entry of DRG®-ELISA:HPL |
|
1992 |
DRG Sp.O.O. is founded in Brno, Czechoslovakia (Czech Rep.) |
|
1992 |
DRG® develops and introduces AFP, HCG, FSH, Prolactin and LH |
|
1993 |
DRG Techsystemsis founded in Moscow, Russa |
|
1993 |
DRG® develops and introduces 17-OH-Progesterone ELISA |
|
1994 |
DRG® develops and introduces DHEA-S, Progesterone, Testosterone, PMSG, and βGH ELISAs |
|
1994 |
DRG® opens DRG Diagnostics Branch Office in Berlin, Germany |
|
1995 |
DRG® develops and Introduces the first worldwide, non-radioactive C-Peptide and Proinsulin Assays |
|
1996 |
DRG® develops and introduces Free Estriol ELISA |
|
1997 |
DRG® develops and introduces Leptin, TGFß,and ß-HCG ELISAs |
|
1998 |
DRG® moves to a new building in Marburg, Germany |
|
1998 |
DRG Instruments GmbH celebrates 25 years in Marburg, Germany |
|
1999 |
DRG® develops and introduces Insulin, PAPP-A, and TGFßII ELISAs |
|
2000 |
DRG® develops and Introduces IGF1, IL-6,Cortisol- Saliva, Androstenedione ELISAs |
|
2000 |
DRG® received certification for QM-System EN ISO9001:1994 DNVon October 27th |
|
2001 |
Dade BehringTechnology is transferred to DRG® production of C5a and PAP - ELISAs |
|
2002 |
DRG® develops and introduces various Saliva -and DHEA –ELISAs |
|
2003 |
DRG® develops and introduces the first worldwide Assay for the measurement of Hepcidin |
|
2003 |
DRG® acquires Novum-Diagnostics in Dietzenbach and takes over production of more than 70 ELISAs for Infectious diseases in the DRG-Novum Branch Lab |
|
2004 |
DRG® develops Tumor Markers, CA 72-4, CA 125, CA 15-3, CA 19-9, Cyfra21-1 and introduces Corticosterone andEstrone ELISAs |
|
2008 |
United States Patent Office issues two patents to DRG International for development of Hepcidindiagnostic kits |
|
2009 |
Introduction to market of DRG® Renin, PLGF, Afamin, Anti-Amyloid, Cripto-1, CYR61, L1-Cam, and NOV Elisa kits |
|
2010 |
United States Patent Office issues two more patents to DRG International for development of Hepcidin diagnostic kits |
|
2010 |
DRG International unveils the DRG: HYBRiD-XL® fully-automatic, random access analyzer for immunoassays and clinical chemistry to revolutionize laboratory procedures! |
|
|
|
DRG International Celebrates 43 Years of Innovation!